首页 > 最新文献

World Journal of Surgical Oncology最新文献

英文 中文
Effect of MPP2 and its DNA methylation levels on prognosis of colorectal cancer patients. MPP2及其DNA甲基化水平对结直肠癌患者预后的影响
IF 2.5 3区 医学 Q3 ONCOLOGY Pub Date : 2024-11-04 DOI: 10.1186/s12957-024-03567-3
Zhizhao Yang, Jiaxing Chen, Zhihao Fu, Dongfeng Deng, Yongqiang Cui, Zhilei Zhao, Xiao Zhang

Colorectal cancer is one of the common malignant tumors with poor prognosis, which is partly due to the lack of an effective biomarker. The purpose of this study is to explore the impact of membrane palmitoylated protein (MPP2) on the prognosis of colorectal cancer patients. We obtained transcriptome data and DNA methylation data of 380 colorectal cancer patients from the Cancer Genome Atlas (TCGA). Then we used a series of bioinformatics analysis methods to reveal the relationship between MPP2 expression, DNA methylation sites, prognosis, immune checkpoint and clinical characteristics of patients. Finally, in vitro experiment and the meta-analysis of thousands of patients further confirmed the impact of MPP2 on the prognosis of colorectal cancer patients and cell migration and proliferation. The expression level of MPP2 is negatively regulated by its DNA methylation sites, which leads to its low expression in colorectal cancer. High expression of MPP2 is an independent prognostic risk factor, which may be a biomarker for colorectal cancer. Moreover, the expression of MPP2 shows a close relationship with immune checkpoint or immune cells infiltration, especially CD4+T cells. In addition, meta-analysis involving 1584 patients from four different data further confirmed that MPP2 was a risk factor for colorectal cancer. Finally, knockdown of MPP2 could significantly inhibit the proliferation of SW480 cells via mTOR signaling pathway. This study was the first to suggest that MPP2 may become a promising biomarker, and has an important role in immune checkpoint or immune cell infiltration in colorectal cancer.

结直肠癌是常见的恶性肿瘤之一,预后较差,部分原因是缺乏有效的生物标志物。本研究旨在探讨膜棕榈酰化蛋白(MPP2)对结直肠癌患者预后的影响。我们从癌症基因组图谱(TCGA)中获得了380名结直肠癌患者的转录组数据和DNA甲基化数据。然后,我们利用一系列生物信息学分析方法揭示了MPP2表达、DNA甲基化位点、预后、免疫检查点和患者临床特征之间的关系。最后,体外实验和数千例患者的荟萃分析进一步证实了MPP2对结直肠癌患者预后、细胞迁移和增殖的影响。MPP2 的表达水平受其 DNA 甲基化位点的负调控,导致其在结直肠癌中的低表达。MPP2 的高表达是一个独立的预后风险因素,可作为结直肠癌的生物标志物。此外,MPP2 的表达与免疫检查点或免疫细胞浸润(尤其是 CD4+T 细胞)有密切关系。此外,涉及四种不同数据的 1584 名患者的荟萃分析进一步证实,MPP2 是结直肠癌的风险因素。最后,敲除 MPP2 可通过 mTOR 信号通路显著抑制 SW480 细胞的增殖。这项研究首次表明,MPP2可能成为一种有前景的生物标志物,并在结直肠癌的免疫检查点或免疫细胞浸润中发挥重要作用。
{"title":"Effect of MPP2 and its DNA methylation levels on prognosis of colorectal cancer patients.","authors":"Zhizhao Yang, Jiaxing Chen, Zhihao Fu, Dongfeng Deng, Yongqiang Cui, Zhilei Zhao, Xiao Zhang","doi":"10.1186/s12957-024-03567-3","DOIUrl":"10.1186/s12957-024-03567-3","url":null,"abstract":"<p><p>Colorectal cancer is one of the common malignant tumors with poor prognosis, which is partly due to the lack of an effective biomarker. The purpose of this study is to explore the impact of membrane palmitoylated protein (MPP2) on the prognosis of colorectal cancer patients. We obtained transcriptome data and DNA methylation data of 380 colorectal cancer patients from the Cancer Genome Atlas (TCGA). Then we used a series of bioinformatics analysis methods to reveal the relationship between MPP2 expression, DNA methylation sites, prognosis, immune checkpoint and clinical characteristics of patients. Finally, in vitro experiment and the meta-analysis of thousands of patients further confirmed the impact of MPP2 on the prognosis of colorectal cancer patients and cell migration and proliferation. The expression level of MPP2 is negatively regulated by its DNA methylation sites, which leads to its low expression in colorectal cancer. High expression of MPP2 is an independent prognostic risk factor, which may be a biomarker for colorectal cancer. Moreover, the expression of MPP2 shows a close relationship with immune checkpoint or immune cells infiltration, especially CD4<sup>+</sup>T cells. In addition, meta-analysis involving 1584 patients from four different data further confirmed that MPP2 was a risk factor for colorectal cancer. Finally, knockdown of MPP2 could significantly inhibit the proliferation of SW480 cells via mTOR signaling pathway. This study was the first to suggest that MPP2 may become a promising biomarker, and has an important role in immune checkpoint or immune cell infiltration in colorectal cancer.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":"22 1","pages":"290"},"PeriodicalIF":2.5,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11533354/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142569664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Letter to Editor: a giant peritoneal loose body in the pelvic cavity. 致编辑的信:盆腔内的巨大腹膜松弛体。
IF 2.5 3区 医学 Q3 ONCOLOGY Pub Date : 2024-11-04 DOI: 10.1186/s12957-024-03574-4
Ke Wu, Qiu-Ling Wang, Wei Ren, Wu-Bin Guo

A response to the case report by Zhang et al. and supplement another case of giant peritoneal loose body discovered due to abdominal pain. A 68-year-old man was admitted to the hospital with abdominal pain. CT revealed an ovoid mass in the pelvis measuring approximately 11.5 × 8.6 × 7.4 cm. During laparotomy, yellowish-white mass was identified within the pelvis. Histological examination revealed that the mass was hyalinized fibrous connective tissue with focal calcification. We report an extremely rare and interesting case.

对 Zhang 等人的病例报告做出回应,并补充另一例因腹痛而发现的巨大腹膜松弛体。一名 68 岁的男性因腹痛入院。CT 显示盆腔内有一个卵圆形肿块,大小约为 11.5 × 8.6 × 7.4 厘米。在腹腔镜手术中,盆腔内发现了黄白色肿块。组织学检查显示,肿块为透明纤维结缔组织,伴局灶性钙化。我们报告了一个极其罕见而有趣的病例。
{"title":"Letter to Editor: a giant peritoneal loose body in the pelvic cavity.","authors":"Ke Wu, Qiu-Ling Wang, Wei Ren, Wu-Bin Guo","doi":"10.1186/s12957-024-03574-4","DOIUrl":"10.1186/s12957-024-03574-4","url":null,"abstract":"<p><p>A response to the case report by Zhang et al. and supplement another case of giant peritoneal loose body discovered due to abdominal pain. A 68-year-old man was admitted to the hospital with abdominal pain. CT revealed an ovoid mass in the pelvis measuring approximately 11.5 × 8.6 × 7.4 cm. During laparotomy, yellowish-white mass was identified within the pelvis. Histological examination revealed that the mass was hyalinized fibrous connective tissue with focal calcification. We report an extremely rare and interesting case.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":"22 1","pages":"289"},"PeriodicalIF":2.5,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11533376/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142569665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical outcomes of conversion surgery after induction immunochemotherapy for borderline resectable T4 esophageal squamous cell carcinoma. 边缘可切除的 T4 食管鳞癌诱导免疫化疗后转换手术的临床疗效。
IF 2.5 3区 医学 Q3 ONCOLOGY Pub Date : 2024-11-01 DOI: 10.1186/s12957-024-03570-8
Chengcheng Zhang, Binwen Xu, Tao Luo, Yue Zhang, Liwen Zhang, Guidong Shi, Maoyong Fu

Background: The current treatment strategies for borderline resectable esophageal squamous cell carcinoma remain controversial. This study aimed to evaluate the efficacy and safety of programmed cell death 1 inhibitors combined with chemotherapy, followed by conversion surgery, for borderline resectable esophageal squamous cell carcinoma.

Methods: Patients with borderline resectable esophageal squamous cell carcinoma treated with induction immunochemotherapy from January 1, 2020 to July 1, 2023 at our hospital were retrospectively analyzed. The primary study outcome was the R0 resection rate. Secondary study outcomes included progression-free survival (PFS), overall survival (OS), pathological complete remission (pCR) rate, and safety.

Results: Forty patients with borderline resectable esophageal squamous cell carcinoma were included in the analysis. The R0 resection rate was 23/40 (57.5%); the conversion success rate was 27/40 (67.5%), and the pCR rate was 11/40 (27.5%). The median follow-up was 23.6 months (95% CI, 19.1-28.2). One-year OS and PFS rates were 77.7% and 71.8%, respectively. The incidence rate of Grade 3-4 adverse events was 10%. There was a significant difference in PFS between patients who underwent surgery and those who did not (P = 0.008, HR: 0.144 95%CI: 0.034-0.606). However, the difference in OS was not significant (P = 0.128, HR: 0.299 95%CI: 0.063-1.416). Patients who achieved clinical downstaging after induction therapy had significantly better OS (P = 0.004 h: 0.110 95%CI: 0.025-0.495) and PFS (P = 0.0016, HR: 0.106 95%CI: 0.026-0.426) compared to those who did not.

Conclusions: Conversion surgery after induction immunochemotherapy is a promising new strategy with a high conversion rate, inspiring R0 resection rate, significant pathological remission rate, and mild toxicity for borderline resectable esophageal squamous cell carcinoma.

背景:目前对边缘可切除食管鳞状细胞癌的治疗策略仍存在争议。本研究旨在评估程序性细胞死亡1抑制剂联合化疗,然后进行转化手术治疗边缘可切除食管鳞癌的有效性和安全性:回顾性分析2020年1月1日至2023年7月1日期间在我院接受诱导免疫化疗治疗的边缘可切除食管鳞癌患者。主要研究结果是R0切除率。次要研究结果包括无进展生存期(PFS)、总生存期(OS)、病理完全缓解率(pCR)和安全性:40名边缘可切除食管鳞状细胞癌患者参与了分析。R0切除率为23/40(57.5%),转化成功率为27/40(67.5%),病理完全缓解率为11/40(27.5%)。中位随访时间为23.6个月(95% CI,19.1-28.2)。一年的OS和PFS率分别为77.7%和71.8%。3-4级不良事件发生率为10%。接受手术和未接受手术的患者的 PFS 有明显差异(P = 0.008,HR:0.144 95%CI:0.034-0.606)。然而,OS 的差异并不显著(P = 0.128,HR:0.299 95%CI:0.063-1.416)。与未达到临床分期的患者相比,诱导治疗后达到临床分期的患者的OS(P = 0.004,HR:0.110 95%CI:0.025-0.495)和PFS(P = 0.0016,HR:0.106 95%CI:0.026-0.426)明显更好:诱导免疫化疗后的转化手术是一种很有前途的新策略,对于边缘可切除食管鳞状细胞癌来说,转化率高、R0切除率高、病理缓解率高且毒性轻微。
{"title":"Clinical outcomes of conversion surgery after induction immunochemotherapy for borderline resectable T4 esophageal squamous cell carcinoma.","authors":"Chengcheng Zhang, Binwen Xu, Tao Luo, Yue Zhang, Liwen Zhang, Guidong Shi, Maoyong Fu","doi":"10.1186/s12957-024-03570-8","DOIUrl":"10.1186/s12957-024-03570-8","url":null,"abstract":"<p><strong>Background: </strong>The current treatment strategies for borderline resectable esophageal squamous cell carcinoma remain controversial. This study aimed to evaluate the efficacy and safety of programmed cell death 1 inhibitors combined with chemotherapy, followed by conversion surgery, for borderline resectable esophageal squamous cell carcinoma.</p><p><strong>Methods: </strong>Patients with borderline resectable esophageal squamous cell carcinoma treated with induction immunochemotherapy from January 1, 2020 to July 1, 2023 at our hospital were retrospectively analyzed. The primary study outcome was the R0 resection rate. Secondary study outcomes included progression-free survival (PFS), overall survival (OS), pathological complete remission (pCR) rate, and safety.</p><p><strong>Results: </strong>Forty patients with borderline resectable esophageal squamous cell carcinoma were included in the analysis. The R0 resection rate was 23/40 (57.5%); the conversion success rate was 27/40 (67.5%), and the pCR rate was 11/40 (27.5%). The median follow-up was 23.6 months (95% CI, 19.1-28.2). One-year OS and PFS rates were 77.7% and 71.8%, respectively. The incidence rate of Grade 3-4 adverse events was 10%. There was a significant difference in PFS between patients who underwent surgery and those who did not (P = 0.008, HR: 0.144 95%CI: 0.034-0.606). However, the difference in OS was not significant (P = 0.128, HR: 0.299 95%CI: 0.063-1.416). Patients who achieved clinical downstaging after induction therapy had significantly better OS (P = 0.004 h: 0.110 95%CI: 0.025-0.495) and PFS (P = 0.0016, HR: 0.106 95%CI: 0.026-0.426) compared to those who did not.</p><p><strong>Conclusions: </strong>Conversion surgery after induction immunochemotherapy is a promising new strategy with a high conversion rate, inspiring R0 resection rate, significant pathological remission rate, and mild toxicity for borderline resectable esophageal squamous cell carcinoma.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":"22 1","pages":"288"},"PeriodicalIF":2.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11529151/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142558962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Improving postoperative survival in cholangiocarcinoma: development of surgical strategies with a screening program in the epidemic region. 提高胆管癌术后存活率:制定外科手术策略,在流行病地区开展筛查计划。
IF 2.5 3区 医学 Q3 ONCOLOGY Pub Date : 2024-10-31 DOI: 10.1186/s12957-024-03573-5
Vasin Thanasukarn, Tharatip Srisuk, Vor Luvira, Theerawee Tipwaratorn, Apiwat Jareanrat, Krit Rattanarak, Khanisara Kraphunpongsakul, Natcha Khuntikeo, Jarin Chindaprasirt, Thanachai Sanlung, Nittaya Chamadol, Supinda Koonmee, Prakasit Sa-Ngiamwibool, Poramate Klanrit, Arporn Wangwiwatsin, Nisana Namwat, Watcharin Loilome, Nattha Muangritdech, Piya Prajumwongs, Nobuyuki Watanabe, Tomoki Ebata, Attapol Titapun

Background: The Cholangiocarcinoma Screening and Care Program (CASCAP) has been launched since 2013 to detect early-stage cholangiocarcinoma and reduce the disease death. However, the clinical utility of the CASCAP remains unclear. To compare survival outcomes between two time periods: before and after 2013, when significant changes in treatment strategies were implemented, and to evaluate the efficacy of the ultrasound-based screening program, in an Asian region endemic for cholangiocarcinoma.

Methods: A single-center retrospective review was conducted in curative-intended resection cholangiocarcinoma from 2002 to 2021. Patents characteristics and survival outcomes were compared between 2002 and 2013 (early period) and 2014 to 2021 (later period).

Results: A total of 1091 patients with intrahepatic (n = 624) or perihilar (n = 467) cholangiocarcinoma was included (early period, n = 658; later period, n = 433). Of 66 (15.2%) patients in the later period were referred by the CASCAP. The incidence of early-staged disease (Stage 0 and 1) was lower in early period compared to later period 16.0% versus 29.1% (p < 0.001); that of positive surgical margin was higher in early period 53.7% versus 40.0% (p < 0.001). A median survival time (MST) was 14 months in early and 40 months in later period (p < 0.001). Subgroup analysis by tumor location, the MST was 13 versus 60 months in early and late periods for intrahepatic tumor (p < 0.001), respectively. While MST in perihilar tumor was 18 versus 31 months in early and late periods(p < 0.001), respectively. By presentation, the MST was 51 vs. 38 months, respectively, with screening and usual presentation (p = 0.06).

Conclusion: Postoperative survival in CCA patients improved more than doubled during the study period. Moreover, the late period demonstrated enhanced early-stage detection, a higher rate of negative surgical margins, and improved survival outcomes.

背景:胆管癌筛查和护理计划(CASCAP)自 2013 年启动,旨在发现早期胆管癌并减少疾病死亡。然而,CASCAP 的临床效用仍不明确。在胆管癌流行的亚洲地区,比较治疗策略发生重大变化的2013年之前和之后两个时期的生存结果,并评估基于超声波的筛查项目的疗效:方法:对2002年至2021年期间接受根治性切除胆管癌的患者进行了单中心回顾性研究。比较了 2002 年至 2013 年(早期)和 2014 年至 2021 年(晚期)的患者特征和生存结果:共纳入1091例肝内(n = 624)或肝周(n = 467)胆管癌患者(早期,n = 658;后期,n = 433)。后期的 66 例(15.2%)患者由 CASCAP 转诊。早期疾病(0 期和 1 期)的发生率为 16.0% 对 29.1%(P,结论):在研究期间,CCA 患者的术后生存率提高了一倍多。此外,晚期患者的早期发现率有所提高,手术切缘阴性率较高,生存率也有所改善。
{"title":"Improving postoperative survival in cholangiocarcinoma: development of surgical strategies with a screening program in the epidemic region.","authors":"Vasin Thanasukarn, Tharatip Srisuk, Vor Luvira, Theerawee Tipwaratorn, Apiwat Jareanrat, Krit Rattanarak, Khanisara Kraphunpongsakul, Natcha Khuntikeo, Jarin Chindaprasirt, Thanachai Sanlung, Nittaya Chamadol, Supinda Koonmee, Prakasit Sa-Ngiamwibool, Poramate Klanrit, Arporn Wangwiwatsin, Nisana Namwat, Watcharin Loilome, Nattha Muangritdech, Piya Prajumwongs, Nobuyuki Watanabe, Tomoki Ebata, Attapol Titapun","doi":"10.1186/s12957-024-03573-5","DOIUrl":"10.1186/s12957-024-03573-5","url":null,"abstract":"<p><strong>Background: </strong>The Cholangiocarcinoma Screening and Care Program (CASCAP) has been launched since 2013 to detect early-stage cholangiocarcinoma and reduce the disease death. However, the clinical utility of the CASCAP remains unclear. To compare survival outcomes between two time periods: before and after 2013, when significant changes in treatment strategies were implemented, and to evaluate the efficacy of the ultrasound-based screening program, in an Asian region endemic for cholangiocarcinoma.</p><p><strong>Methods: </strong>A single-center retrospective review was conducted in curative-intended resection cholangiocarcinoma from 2002 to 2021. Patents characteristics and survival outcomes were compared between 2002 and 2013 (early period) and 2014 to 2021 (later period).</p><p><strong>Results: </strong>A total of 1091 patients with intrahepatic (n = 624) or perihilar (n = 467) cholangiocarcinoma was included (early period, n = 658; later period, n = 433). Of 66 (15.2%) patients in the later period were referred by the CASCAP. The incidence of early-staged disease (Stage 0 and 1) was lower in early period compared to later period 16.0% versus 29.1% (p < 0.001); that of positive surgical margin was higher in early period 53.7% versus 40.0% (p < 0.001). A median survival time (MST) was 14 months in early and 40 months in later period (p < 0.001). Subgroup analysis by tumor location, the MST was 13 versus 60 months in early and late periods for intrahepatic tumor (p < 0.001), respectively. While MST in perihilar tumor was 18 versus 31 months in early and late periods(p < 0.001), respectively. By presentation, the MST was 51 vs. 38 months, respectively, with screening and usual presentation (p = 0.06).</p><p><strong>Conclusion: </strong>Postoperative survival in CCA patients improved more than doubled during the study period. Moreover, the late period demonstrated enhanced early-stage detection, a higher rate of negative surgical margins, and improved survival outcomes.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":"22 1","pages":"287"},"PeriodicalIF":2.5,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11526638/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142547873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Axillary lymph node dissection is not required for breast cancer patients with minimal axillary residual disease after neoadjuvant chemotherapy. 新辅助化疗后腋窝残留病灶极小的乳腺癌患者无需进行腋窝淋巴结清扫。
IF 2.5 3区 医学 Q3 ONCOLOGY Pub Date : 2024-10-31 DOI: 10.1186/s12957-024-03547-7
Mahmut Muslumanoglu, Baran Mollavelioglu, Neslihan Cabioglu, Selman Emiroglu, Mustafa Tukenmez, Hasan Karanlık, Tolga Ozmen, Ravza Yılmaz, Rana Gunoz Comert, Semen Onder, Aysel Bayram, Duygu Has Simsek, Melis Oflas, Kamuran Ibis, Adnan Aydıner, Vahit Ozmen, Abdullah Igci

Background: Sentinel lymph node biopsy (SLNB) is widely used in patients who receive neoadjuvant chemotherapy (NAC). Still, axillary lymph node dissection (ALND) is recommended for patients with any axillary residual disease after NAC. The necessity of ALND in patients with minimal axillary disease is unclear. We aim to investigate regional recurrence rates in patients with limited axillary residual disease after NAC underwent SLNB + image-tailored axillary surgery and adjuvant radiotherapy (RT).

Methods: Patients with clinical stages were T1-3 and N1 at the time of diagnosis, clinically good or complete axillary response after NAC, and limited axillary residue (≤ 3 pathological lymph nodes) with favorable response to NAC in the final pathological examination were included in the study. All patients underwent SLNB + image-tailored axillary surgery. Peripheral lymphatic radiotherapy was applied, and no further surgery was performed in patients with compatible radiology and pathology results.

Results: Our study, which evaluated 139 patients with a median age of 47 years, found that the median number of excised lymph nodes was 4. Notably, 46% of patients had between 1 and 3 lymph nodes excised, while 45% had between 4 and 6. Only 9% of patients had ≥ 7 lymph nodes. 83(60%) of the patients underwent breast-conserving surgery (BCS), and 56(40%) underwent mastectomy. The study's median follow-up period was 44 months. During this duration, one breast recurrence (0.7%), one supraclavicular recurrence (0.7%), and six systemic recurrences (4.3%) were observed. No axillary recurrence occurred within the follow-up period.

Conclusions: Patients presenting with pathological-suspicious ≤ 3 lymph nodes on imaging and showing a good response to NAC can be considered suitable candidates for SLNB + image-tailored axillary surgery, followed by adjuvant RT instead of ALND.

背景:前哨淋巴结活检(SLNB)广泛应用于接受新辅助化疗(NAC)的患者。但对于接受新辅助化疗后有腋窝残留疾病的患者,仍建议进行腋窝淋巴结清扫术(ALND)。对于腋窝病变极小的患者,是否有必要进行腋窝淋巴结清扫尚不清楚。我们旨在研究接受 SLNB + 图像定制腋窝手术和辅助放疗(RT)的 NAC 后腋窝残留病灶有限的患者的区域复发率:研究对象包括确诊时临床分期为T1-3和N1、NAC术后临床反应良好或腋窝完全反应、最终病理检查显示NAC术后反应良好的局限性腋窝残留(病理淋巴结≤3个)患者。所有患者都接受了SLNB+图像定制腋窝手术。对放射学和病理学结果符合要求的患者,采用外周淋巴放疗,不再进行手术:我们的研究共评估了 139 名患者,中位年龄为 47 岁,发现切除淋巴结的中位数为 4 个,值得注意的是,46% 的患者切除了 1 至 3 个淋巴结,45% 的患者切除了 4 至 6 个淋巴结。只有 9% 的患者淋巴结数量≥ 7 个。83(60%)名患者接受了保乳手术(BCS),56(40%)名患者接受了乳房切除术。研究的中位随访期为 44 个月。在此期间,观察到一次乳房复发(0.7%)、一次锁骨上复发(0.7%)和六次全身复发(4.3%)。随访期间未出现腋窝复发:结论:影像学显示病理可疑淋巴结≤3个且对NAC反应良好的患者可考虑接受SLNB+影像学定制的腋窝手术,随后进行辅助RT,而不是ALND。
{"title":"Axillary lymph node dissection is not required for breast cancer patients with minimal axillary residual disease after neoadjuvant chemotherapy.","authors":"Mahmut Muslumanoglu, Baran Mollavelioglu, Neslihan Cabioglu, Selman Emiroglu, Mustafa Tukenmez, Hasan Karanlık, Tolga Ozmen, Ravza Yılmaz, Rana Gunoz Comert, Semen Onder, Aysel Bayram, Duygu Has Simsek, Melis Oflas, Kamuran Ibis, Adnan Aydıner, Vahit Ozmen, Abdullah Igci","doi":"10.1186/s12957-024-03547-7","DOIUrl":"10.1186/s12957-024-03547-7","url":null,"abstract":"<p><strong>Background: </strong>Sentinel lymph node biopsy (SLNB) is widely used in patients who receive neoadjuvant chemotherapy (NAC). Still, axillary lymph node dissection (ALND) is recommended for patients with any axillary residual disease after NAC. The necessity of ALND in patients with minimal axillary disease is unclear. We aim to investigate regional recurrence rates in patients with limited axillary residual disease after NAC underwent SLNB + image-tailored axillary surgery and adjuvant radiotherapy (RT).</p><p><strong>Methods: </strong>Patients with clinical stages were T1-3 and N1 at the time of diagnosis, clinically good or complete axillary response after NAC, and limited axillary residue (≤ 3 pathological lymph nodes) with favorable response to NAC in the final pathological examination were included in the study. All patients underwent SLNB + image-tailored axillary surgery. Peripheral lymphatic radiotherapy was applied, and no further surgery was performed in patients with compatible radiology and pathology results.</p><p><strong>Results: </strong>Our study, which evaluated 139 patients with a median age of 47 years, found that the median number of excised lymph nodes was 4. Notably, 46% of patients had between 1 and 3 lymph nodes excised, while 45% had between 4 and 6. Only 9% of patients had ≥ 7 lymph nodes. 83(60%) of the patients underwent breast-conserving surgery (BCS), and 56(40%) underwent mastectomy. The study's median follow-up period was 44 months. During this duration, one breast recurrence (0.7%), one supraclavicular recurrence (0.7%), and six systemic recurrences (4.3%) were observed. No axillary recurrence occurred within the follow-up period.</p><p><strong>Conclusions: </strong>Patients presenting with pathological-suspicious ≤ 3 lymph nodes on imaging and showing a good response to NAC can be considered suitable candidates for SLNB + image-tailored axillary surgery, followed by adjuvant RT instead of ALND.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":"22 1","pages":"286"},"PeriodicalIF":2.5,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11526682/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142547872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The diagnostic accuracy of urine-derived exosomes for bladder cancer: a systematic review and meta-analysis. 尿液外泌体对膀胱癌的诊断准确性:系统综述和荟萃分析。
IF 2.5 3区 医学 Q3 ONCOLOGY Pub Date : 2024-10-29 DOI: 10.1186/s12957-024-03569-1
Chunyue Long, Hongjin Shi, Jinyu Li, Lijian Chen, Mei Lv, Wenlin Tai, Haifeng Wang, Yiheng Xu

Introduction: Urine-derived exosomes could potentially be biomarkers for bladder cancer (BC) diagnosis. This study aimed to systematically evaluate the diagnostic worth of urine-derived exosomes in BC patients through a meta-analysis of diverse studies.

Methods: A systematic search was carried out in PubMed, Web of Science, Embase, Cochrane, and CNKI databases to obtain the literature concerning the diagnosis of BC via urine-derived exosomes. A literature retrieval strategy was devised to pick articles and extract needed data from the literature. QUADS-2 was used to evaluate the quality of the included literatures, and the aggregated diagnostic effect was assessed by calculating the area under the aggregated SROC curve. All statistical analyses and plots were conducted with STATA 14.0 and RevMan5.3.

Results: A total of 678 articles were retrieved by means of the search strategy of the online database. Through screening, 21 articles were obtained, involving 3348 participants and 77 studies. The meta-analysis of the results indicated that urinary exosomes had a combined sensitivity of 0.75, a specificity of 0.77, and a combined AUC of 0.83 for the diagnosis of BC, suggesting that urine-derived exosomes have a relatively satisfactory diagnostic effect in the detection of BC. Among the subgroups classified by biomarker, long non-coding RNAs (lncRNAs) had the highest comprehensive sensitivity (SEN = 0.78), and miRNAs had the highest comprehensive specificity (SPN = 0.81). In other subgroup analyses, the biomarker panel for multiple exosomes combined diagnosis demonstrated the best diagnostic efficacy, with a combined the area under the curve ( AUC) of 0.87.

Conclusions: As a novel biomarker, urine-derived exosomes have significant diagnostic prospects in the diagnosis of BC. Nevertheless, their application in clinical settings still demands a considerable number of clinical trials to confirm their clinical feasibility and practicability.

导言:尿液中的外泌体有可能成为诊断膀胱癌(BC)的生物标记物。本研究旨在通过对不同研究进行荟萃分析,系统评估尿源性外泌体在膀胱癌患者中的诊断价值:方法:我们在PubMed、Web of Science、Embase、Cochrane和CNKI数据库中进行了系统检索,以获取通过尿源性外泌体诊断BC的相关文献。我们设计了一种文献检索策略,从文献中挑选文章并提取所需的数据。采用QUADS-2评估所收录文献的质量,并通过计算综合SROC曲线下的面积来评估综合诊断效果。所有统计分析和绘图均使用 STATA 14.0 和 RevMan5.3 进行:通过在线数据库的检索策略,共检索到 678 篇文章。通过筛选,共获得 21 篇文章,涉及 3348 名参与者和 77 项研究。荟萃分析结果表明,尿液外泌体诊断BC的综合灵敏度为0.75,特异度为0.77,综合AUC为0.83,表明尿液外泌体在检测BC方面具有较为理想的诊断效果。在按生物标志物分类的亚组中,长非编码RNA(lncRNA)的综合灵敏度最高(SEN = 0.78),miRNA的综合特异性最高(SPN = 0.81)。在其他亚组分析中,多种外泌体联合诊断的生物标记物面板显示出最佳诊断效果,曲线下综合面积(AUC)为0.87:作为一种新型生物标志物,尿源性外泌体在诊断乳腺癌方面具有重要的诊断前景。尽管如此,将其应用于临床仍需要大量的临床试验来证实其临床可行性和实用性。
{"title":"The diagnostic accuracy of urine-derived exosomes for bladder cancer: a systematic review and meta-analysis.","authors":"Chunyue Long, Hongjin Shi, Jinyu Li, Lijian Chen, Mei Lv, Wenlin Tai, Haifeng Wang, Yiheng Xu","doi":"10.1186/s12957-024-03569-1","DOIUrl":"10.1186/s12957-024-03569-1","url":null,"abstract":"<p><strong>Introduction: </strong>Urine-derived exosomes could potentially be biomarkers for bladder cancer (BC) diagnosis. This study aimed to systematically evaluate the diagnostic worth of urine-derived exosomes in BC patients through a meta-analysis of diverse studies.</p><p><strong>Methods: </strong>A systematic search was carried out in PubMed, Web of Science, Embase, Cochrane, and CNKI databases to obtain the literature concerning the diagnosis of BC via urine-derived exosomes. A literature retrieval strategy was devised to pick articles and extract needed data from the literature. QUADS-2 was used to evaluate the quality of the included literatures, and the aggregated diagnostic effect was assessed by calculating the area under the aggregated SROC curve. All statistical analyses and plots were conducted with STATA 14.0 and RevMan5.3.</p><p><strong>Results: </strong>A total of 678 articles were retrieved by means of the search strategy of the online database. Through screening, 21 articles were obtained, involving 3348 participants and 77 studies. The meta-analysis of the results indicated that urinary exosomes had a combined sensitivity of 0.75, a specificity of 0.77, and a combined AUC of 0.83 for the diagnosis of BC, suggesting that urine-derived exosomes have a relatively satisfactory diagnostic effect in the detection of BC. Among the subgroups classified by biomarker, long non-coding RNAs (lncRNAs) had the highest comprehensive sensitivity (SEN = 0.78), and miRNAs had the highest comprehensive specificity (SPN = 0.81). In other subgroup analyses, the biomarker panel for multiple exosomes combined diagnosis demonstrated the best diagnostic efficacy, with a combined the area under the curve ( AUC) of 0.87.</p><p><strong>Conclusions: </strong>As a novel biomarker, urine-derived exosomes have significant diagnostic prospects in the diagnosis of BC. Nevertheless, their application in clinical settings still demands a considerable number of clinical trials to confirm their clinical feasibility and practicability.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":"22 1","pages":"285"},"PeriodicalIF":2.5,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11520875/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142547874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Fibrinogen to pre-albumin ratio is an independent prognostic index for patients with pancreatic ductal adenocarcinoma after radical resection. 纤维蛋白原与白蛋白前比率是胰腺导管腺癌患者根治性切除术后的独立预后指标。
IF 2.5 3区 医学 Q3 ONCOLOGY Pub Date : 2024-10-28 DOI: 10.1186/s12957-024-03524-0
Shaofei Chang, Yiping Zou, Jing Huang, Zhifei Li, Yuexiang Liang, Song Gao

Background: This study aims to elucidate the significance of the preoperative fibrinogen to pre-albumin ratio (FPR) in predicting the prognosis of pancreatic ductal adenocarcinoma (PDAC), a correlation not extensively explored previously.

Methods: A cohort of 563 patients diagnosed with PDAC and subjected to radical surgical resection was examined. We meticulously documented a range of inflammatory markers, clinical-pathological features, and oncological outcomes. The prognostic value of preoperative FPR was assessed using Kaplan-Meier survival analysis and Cox proportional hazards regression modeling. Furthermore, the predictive accuracy of FPR was evaluated through time-dependent receiver operating characteristic (ROC) curves and decision curve analyses (DCA).

Results: The determined optimal threshold for FPR was 14.77, which facilitated the stratification of patients into groups with low and high FPR levels. Notably, patients in the high FPR cohort exhibited significantly reduced recurrence-free survival (RFS) and overall survival (OS) rates compared to their low FPR counterparts. Multivariate Cox regression analysis underscored FPR as an independent prognostic indicator for both RFS and OS. In comparison to the neutrophil-to-lymphocyte ratio (NLR), FPR demonstrated superior prognostic accuracy and clinical utility.

Conclusion: The preoperative fibrinogen to pre-albumin ratio serves as an independent prognostic marker for RFS and OS among PDAC patients undergoing radical resection. Our findings suggest that FPR could be a valuable addition to the current prognostic models, potentially guiding therapeutic decision-making and patient management strategies in PDAC.

研究背景本研究旨在阐明术前纤维蛋白原与前白蛋白比值(FPR)在预测胰腺导管腺癌(PDAC)预后方面的意义,这一相关性此前并未得到广泛探讨:我们对 563 例确诊为 PDAC 并接受根治性手术切除的患者进行了研究。我们仔细记录了一系列炎症指标、临床病理特征和肿瘤预后。我们使用卡普兰-梅耶生存分析和考克斯比例危险回归模型评估了术前 FPR 的预后价值。此外,还通过与时间相关的接收者操作特征曲线(ROC)和决策曲线分析(DCA)评估了FPR的预测准确性:结果:确定的 FPR 最佳阈值为 14.77,这有助于将患者分为低 FPR 水平组和高 FPR 水平组。值得注意的是,与低FPR组相比,高FPR组患者的无复发生存率(RFS)和总生存率(OS)明显降低。多变量 Cox 回归分析显示,FPR 是影响无复发生存期(RFS)和总生存期(OS)的独立预后指标。与中性粒细胞与淋巴细胞比值(NLR)相比,FPR显示出更高的预后准确性和临床实用性:结论:术前纤维蛋白原与白蛋白比值是接受根治性切除术的PDAC患者RFS和OS的独立预后指标。我们的研究结果表明,纤维蛋白原与白蛋白比值可作为现有预后模型的重要补充,为 PDAC 的治疗决策和患者管理策略提供潜在指导。
{"title":"Fibrinogen to pre-albumin ratio is an independent prognostic index for patients with pancreatic ductal adenocarcinoma after radical resection.","authors":"Shaofei Chang, Yiping Zou, Jing Huang, Zhifei Li, Yuexiang Liang, Song Gao","doi":"10.1186/s12957-024-03524-0","DOIUrl":"10.1186/s12957-024-03524-0","url":null,"abstract":"<p><strong>Background: </strong>This study aims to elucidate the significance of the preoperative fibrinogen to pre-albumin ratio (FPR) in predicting the prognosis of pancreatic ductal adenocarcinoma (PDAC), a correlation not extensively explored previously.</p><p><strong>Methods: </strong>A cohort of 563 patients diagnosed with PDAC and subjected to radical surgical resection was examined. We meticulously documented a range of inflammatory markers, clinical-pathological features, and oncological outcomes. The prognostic value of preoperative FPR was assessed using Kaplan-Meier survival analysis and Cox proportional hazards regression modeling. Furthermore, the predictive accuracy of FPR was evaluated through time-dependent receiver operating characteristic (ROC) curves and decision curve analyses (DCA).</p><p><strong>Results: </strong>The determined optimal threshold for FPR was 14.77, which facilitated the stratification of patients into groups with low and high FPR levels. Notably, patients in the high FPR cohort exhibited significantly reduced recurrence-free survival (RFS) and overall survival (OS) rates compared to their low FPR counterparts. Multivariate Cox regression analysis underscored FPR as an independent prognostic indicator for both RFS and OS. In comparison to the neutrophil-to-lymphocyte ratio (NLR), FPR demonstrated superior prognostic accuracy and clinical utility.</p><p><strong>Conclusion: </strong>The preoperative fibrinogen to pre-albumin ratio serves as an independent prognostic marker for RFS and OS among PDAC patients undergoing radical resection. Our findings suggest that FPR could be a valuable addition to the current prognostic models, potentially guiding therapeutic decision-making and patient management strategies in PDAC.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":"22 1","pages":"284"},"PeriodicalIF":2.5,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11520588/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142523233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Risk factor analysis and prediction model construction for contralateral central lymph node metastasis in unilateral papillary thyroid carcinoma : Sex, extrathyroidal tumor extension (ETE), tumor diameter and ipsilateral central lymph node metastasis (ICLNM) are risk factor for unilateral papillary thyroid carcinoma (UPTC): a case control study. 单侧甲状腺乳头状癌对侧中央淋巴结转移的危险因素分析和预测模型构建:性别、甲状腺外肿瘤扩展(ETE)、肿瘤直径和同侧中央淋巴结转移(ICLNM)是单侧甲状腺乳头状癌(UPTC)的危险因素:一项病例对照研究。
IF 2.5 3区 医学 Q3 ONCOLOGY Pub Date : 2024-10-25 DOI: 10.1186/s12957-024-03565-5
Jihao Qin, Xiaowen Fang, Chenxi Liang, Siyu Li, Xueyu Zeng, Hancheng Jiang, Zhu Chen, Jie-Hua Li

Objective: To investigate contralateral central lymph node metastasis (CCLNM) in patients with unilateral papillary thyroid carcinoma (UPTC). To provide a reference for clinical decision-making, a prediction model for the probability of CCLNM was established.

Method: The clinicopathological data of 221 UPTC patients who underwent surgical treatment were retrospectively analyzed. Univariate and multivariate logistic regression analyses were performed to determine the independent risk factors for CCLNM according to clinicopathological characteristics, construct a prediction model to construct a visual nomogram, and evaluate the model.

Results: According to univariate and multivariate logistic regression analyses, sex (P = 0.01, OR: 3.790, 95% CI: 1.373-10.465), extrathyroidal tumor extension (ETE) (P = 0.040, OR: 6.364, 95% CI: 1.083-37.381), tumor diameter (P = 0.010, OR: 3.674, 95% CI: 1.372-9.839) and ipsilateral central lymph node metastasis (ICLNM) (P < 0.001, OR: 38.552, 95% CI: 2.675-27.342) were found to be independent risk factors for CCLNM and were used to construct a nomogram for internal verification. The ROC curve had an AUC of 0.852 in the training group and an AUC of 0.848 in the verification group, and the calibration curve indicated that the prediction probability of the model was consistent with the actual probability. Finally, the analysis of the decision curve showed that the model has good application value in clinical decision-making.

Conclusion: Sex, ETE, tumor size, and ICLNM emerged as independent risk factors for CCLNM in UPTC patients. A predictive model was therefore developed, harnessing these variables to enable an objective, personalized estimation of CCLNM risk. This tool offers valuable insights to inform surgical planning and optimize treatment strategies for UPTC management.

目的研究单侧甲状腺乳头状癌(UPTC)患者的对侧中央淋巴结转移(CCLNM)。为临床决策提供参考,建立CCLNM发生概率的预测模型:方法:回顾性分析了221例接受手术治疗的单侧甲状腺乳头状癌患者的临床病理数据。方法:回顾性分析221例接受手术治疗的UPTC患者的临床病理资料,进行单变量和多变量Logistic回归分析,根据临床病理特征确定CCLNM的独立危险因素,建立预测模型,构建可视化提名图,并对模型进行评估:根据单变量和多变量逻辑回归分析,性别(P = 0.01,OR:3.790,95% CI:1.373-10.465)、甲状腺外肿瘤扩展(ETE)(P = 0.040,OR:6.364,95% CI:1.083-37.381)、肿瘤直径(P = 0.010,OR:3.674,95% CI:1.372-9.839)和同侧中央淋巴结转移(ICLNM)(P 结论:P = 0.010):性别、ETE、肿瘤大小和ICLNM是UPTC患者发生CCLNM的独立风险因素。因此,我们开发了一个预测模型,利用这些变量对CCLNM风险进行客观、个性化的评估。该工具可为手术规划提供有价值的见解,并优化UPTC管理的治疗策略。
{"title":"Risk factor analysis and prediction model construction for contralateral central lymph node metastasis in unilateral papillary thyroid carcinoma : Sex, extrathyroidal tumor extension (ETE), tumor diameter and ipsilateral central lymph node metastasis (ICLNM) are risk factor for unilateral papillary thyroid carcinoma (UPTC): a case control study.","authors":"Jihao Qin, Xiaowen Fang, Chenxi Liang, Siyu Li, Xueyu Zeng, Hancheng Jiang, Zhu Chen, Jie-Hua Li","doi":"10.1186/s12957-024-03565-5","DOIUrl":"10.1186/s12957-024-03565-5","url":null,"abstract":"<p><strong>Objective: </strong>To investigate contralateral central lymph node metastasis (CCLNM) in patients with unilateral papillary thyroid carcinoma (UPTC). To provide a reference for clinical decision-making, a prediction model for the probability of CCLNM was established.</p><p><strong>Method: </strong>The clinicopathological data of 221 UPTC patients who underwent surgical treatment were retrospectively analyzed. Univariate and multivariate logistic regression analyses were performed to determine the independent risk factors for CCLNM according to clinicopathological characteristics, construct a prediction model to construct a visual nomogram, and evaluate the model.</p><p><strong>Results: </strong>According to univariate and multivariate logistic regression analyses, sex (P = 0.01, OR: 3.790, 95% CI: 1.373-10.465), extrathyroidal tumor extension (ETE) (P = 0.040, OR: 6.364, 95% CI: 1.083-37.381), tumor diameter (P = 0.010, OR: 3.674, 95% CI: 1.372-9.839) and ipsilateral central lymph node metastasis (ICLNM) (P < 0.001, OR: 38.552, 95% CI: 2.675-27.342) were found to be independent risk factors for CCLNM and were used to construct a nomogram for internal verification. The ROC curve had an AUC of 0.852 in the training group and an AUC of 0.848 in the verification group, and the calibration curve indicated that the prediction probability of the model was consistent with the actual probability. Finally, the analysis of the decision curve showed that the model has good application value in clinical decision-making.</p><p><strong>Conclusion: </strong>Sex, ETE, tumor size, and ICLNM emerged as independent risk factors for CCLNM in UPTC patients. A predictive model was therefore developed, harnessing these variables to enable an objective, personalized estimation of CCLNM risk. This tool offers valuable insights to inform surgical planning and optimize treatment strategies for UPTC management.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":"22 1","pages":"280"},"PeriodicalIF":2.5,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11515390/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142509251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinicopathologic characterization of secretory carcinoma of salivary gland. 唾液腺分泌性癌的临床病理学特征。
IF 2.5 3区 医学 Q3 ONCOLOGY Pub Date : 2024-10-25 DOI: 10.1186/s12957-024-03561-9
Fei Han, Feng Liu, Hao Wang, Yanchao Qin, Qian Lu, Xuesong Wu, Zhen Guo, Xinrong Nan

Background: To investigate the clinicopathologic characteristics, therapeutic methods, and prognosis of secretory carcinoma of salivary gland (SCSG).

Methods: The clinicopathologic data of 13 patients with SCSG admitted to Shanxi Cancer Hospital from January 2018 to June 2023 were retrospectively analyzed, and a literature review was performed.

Results: A total of eight males and five females aged 22-78 years old were enrolled, and they commonly presented with painless masses in the parotid or submandibular gland. They all underwent surgical treatment, accompanied by typical pathological examinations postoperatively. Fluorescence in situ hybridization (FISH) was conducted in seven cases, the results were all positive, and no gene fusion other than ETV6-NTRK3 was found. Two patients developed local relapse during follow-up, both of which were in the surgical area. By the end of the follow-up, 12 patients survived and one patient died.

Conclusions: SCSG is a rare low-grade malignancy with a good prognosis. Pathological and immunohistochemical characteristics are the key to secretory carcinoma (SC) diagnosis, and surgical excision is the major treatment means for SCSG. Whether to perform simultaneous cervical lymph node dissection and other adjuvant therapies should be determined based on the pathological stage and the presence or absence of high-risk factors.

背景:研究唾液腺分泌性癌(SCSG)的临床病理特征、治疗方法和预后:目的:探讨唾液腺分泌性癌(SCSG)的临床病理特点、治疗方法及预后:回顾性分析山西省肿瘤医院2018年1月至2023年6月收治的13例SCSG患者的临床病理资料,并进行文献综述:入选患者共8男5女,年龄22-78岁,常见表现为腮腺或颌下腺无痛性肿块。他们都接受了手术治疗,术后进行了典型的病理检查。对7例患者进行了荧光原位杂交(FISH),结果均为阳性,除ETV6-NTRK3外未发现其他基因融合。两名患者在随访期间出现局部复发,均发生在手术区域。随访结束时,12名患者存活,1名患者死亡:SCSG是一种罕见的低度恶性肿瘤,预后良好。病理和免疫组化特征是诊断分泌性癌(SC)的关键,手术切除是SCSG的主要治疗手段。是否同时进行宫颈淋巴结清扫术和其他辅助治疗,应根据病理分期和有无高危因素来决定。
{"title":"Clinicopathologic characterization of secretory carcinoma of salivary gland.","authors":"Fei Han, Feng Liu, Hao Wang, Yanchao Qin, Qian Lu, Xuesong Wu, Zhen Guo, Xinrong Nan","doi":"10.1186/s12957-024-03561-9","DOIUrl":"10.1186/s12957-024-03561-9","url":null,"abstract":"<p><strong>Background: </strong>To investigate the clinicopathologic characteristics, therapeutic methods, and prognosis of secretory carcinoma of salivary gland (SCSG).</p><p><strong>Methods: </strong>The clinicopathologic data of 13 patients with SCSG admitted to Shanxi Cancer Hospital from January 2018 to June 2023 were retrospectively analyzed, and a literature review was performed.</p><p><strong>Results: </strong>A total of eight males and five females aged 22-78 years old were enrolled, and they commonly presented with painless masses in the parotid or submandibular gland. They all underwent surgical treatment, accompanied by typical pathological examinations postoperatively. Fluorescence in situ hybridization (FISH) was conducted in seven cases, the results were all positive, and no gene fusion other than ETV6-NTRK3 was found. Two patients developed local relapse during follow-up, both of which were in the surgical area. By the end of the follow-up, 12 patients survived and one patient died.</p><p><strong>Conclusions: </strong>SCSG is a rare low-grade malignancy with a good prognosis. Pathological and immunohistochemical characteristics are the key to secretory carcinoma (SC) diagnosis, and surgical excision is the major treatment means for SCSG. Whether to perform simultaneous cervical lymph node dissection and other adjuvant therapies should be determined based on the pathological stage and the presence or absence of high-risk factors.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":"22 1","pages":"282"},"PeriodicalIF":2.5,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11515321/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142509248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction: Efficacy of neoadjuvant chemotherapy combined with prophylactic intraperitoneal hyperthermic chemotherapy for patients diagnosed with clinical T4 gastric cancer who underwent laparoscopic radical gastrectomy: a retrospective cohort study based on propensity score matching. 更正:对接受腹腔镜胃癌根治术的临床 T4 期胃癌患者进行新辅助化疗联合预防性腹腔热化疗的疗效:基于倾向评分匹配的回顾性队列研究。
IF 2.5 3区 医学 Q3 ONCOLOGY Pub Date : 2024-10-25 DOI: 10.1186/s12957-024-03555-7
Chen-Bin Lv, Lin-Yan Tong, Wei-Ming Zeng, Qiu-Xian Chen, Shun-Yong Fang, Yu-Qin Sun, Li-Sheng Cai
{"title":"Correction: Efficacy of neoadjuvant chemotherapy combined with prophylactic intraperitoneal hyperthermic chemotherapy for patients diagnosed with clinical T4 gastric cancer who underwent laparoscopic radical gastrectomy: a retrospective cohort study based on propensity score matching.","authors":"Chen-Bin Lv, Lin-Yan Tong, Wei-Ming Zeng, Qiu-Xian Chen, Shun-Yong Fang, Yu-Qin Sun, Li-Sheng Cai","doi":"10.1186/s12957-024-03555-7","DOIUrl":"https://doi.org/10.1186/s12957-024-03555-7","url":null,"abstract":"","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":"22 1","pages":"283"},"PeriodicalIF":2.5,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11503933/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142509249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
World Journal of Surgical Oncology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1